Methods for diagnosis, prognosis, and of determining the treatment for acute leukaemia

摘要

A method of diagnosing, prognosing, determining progression, predicting a response to treatment or choosing a treatment for acute leukaemia, myelodysplastic syndrome, or myeloproliferative neoplasms is disclosed comprising classifying hematopoietic cells associated with the aforementioned conditions by a method comprising subjecting said cells to no modulator, or to CD40L, determining the activation level p-CREB in the cells, and classifying the hematopoietic cells based on the activation levels of p-CREB, and making decisions on diagnosis, prognosis, progression, response to treatment or selection of treatment based on said classification. Methods involving the addition of the modulators FLT3L, IGF-1, IL-27, IL-3, IL-6, M-CSF, SCF, Thapsigargin, SDF-1 α, or PMA, before determining the activation level of p-CREB are also claimed. The activation level of p-Erk, p- plcγ2, p-S6, p-Stat 3, p-Stat 5, p-SLP-76, p-Lck, p-Akt, p-Stat 6, p-ChK2, c-PARP, p-Stat 1, cytochrome C, and multiple combinations of at least three activatable elements may also be measured.